Apollo Awaits First Proof-Of-Concept Data For Atopic Dermatitis Drug

Having built its portfolio from university collaborations and targeted in-licensing, the UK firm now hopes to validate its business model with Phase II readouts in 2025.

Apollo Therapeutics is working with leading UK universities to translate research into novel drugs, but is also in-licensing biopharma assets. (Shutterstock)

Apollo Therapeutics is about to find out if its novel portfolio-building approach to biotech can pay off, starting with a Phase II readout from its IL-18 candidate in atopic dermatitis.

The UK-headquartered company has been around since 2015 and works with the country’s universities to translate breakthroughs in basic science...

More from Start-Ups & SMEs

More from Alimentary/Metabolic